Ignite Creation Date:
2025-12-26 @ 10:34 AM
Ignite Modification Date:
2026-01-13 @ 10:02 AM
Study NCT ID:
NCT04874428
Status:
RECRUITING
Last Update Posted:
2024-12-24
First Post:
2021-04-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
Sponsor:
Insel Gruppe AG, University Hospital Bern
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Liver Cirrhosis | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Rivaroxaban | View |
| None | Apixaban | View |
| None | Factor Xa Inhibitors | View |
| None | Antithrombins | View |
| None | Serine Proteinase Inhibitors | View |
| None | Protease Inhibitors | View |
| None | Enzyme Inhibitors | View |
| None | Anticoagulants | View |
| None | Pharmacokinetics | View |
| None | Pharmacodynamics | View |
| None | Thromboembolism | View |
| None | Venous Thromboembolism | View |
| None | Embolism and Thrombosis | View |
| None | Vascular Diseases | View |
| None | Cardiovascular Diseases | View |
| None | Liver Cirrhosis | View |
| None | Liver Diseases | View |